ArticleUrologic oncology2017
Treatment of men with high-risk prostate cancer based on race, insurance coverage, and access to advanced technology.
Article in Urologic oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Impact of Social Determinants of Health on Post-operative Outcomes Following Robotic Radical Prostatectomy.Current oncology reports · 2025Pooled it
- Understanding the hospital safety net Hospital resource limitations impact prostate cancer treatment beyond socioeconomic disparities.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.Prostate cancer and prostatic diseases · 2024Article
- Understanding the Role of Urology Practice Organization and Racial Composition in Prostate Cancer Treatment Disparities.JCO oncology practice · 2023Article
- Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer.Cancers · 2023Review
- Population demographics in geographic proximity to hospitals with robotic platforms do not correlate with disparities in access to robotic surgery.Surgical endoscopy · 2021Article
- Adherence to Guideline-Concordant Care and Its Effect on Survival in Black Patients with Head and Neck Cancers: A SEER-Medicare Analysis.The oncologist · 2021Article
- Impact of cancer service centralisation on the radical treatment of men with high-risk and locally advanced prostate cancer: A national cross-sectional analysis in England.International journal of cancer · 2019Article
- Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population.Journal of the National Comprehensive Cancer Network : JNCCN · 2018Article
- Demographic, presentation, and treatment factors and racial disparities in ovarian cancer hospitalization outcomes.Cancer causes & control : CCC · 2018Article
- African-American Prostate Cancer Disparities.Current urology reports · 2017Review
- Disparities in the Utilization of Radiation Therapy for Prostate Cancer in the United States: A Comprehensive Review.Advances in radiation oncologyReview
- Racial disparities in guideline-concordant cancer care and mortality in the United States.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
purposeWe characterized factors related to nondefinitive management (NDM) of patients with high-risk prostate cancer and assessed impact from race, insurance status, and facility-level volume of technologically advanced prostate cancer treatments (i.e., intensity-modulated radiation therapy, robotic-assisted laparoscopic radical prostatectomy) on this outcome.
methodsWe identified men with high-risk localized prostate cancer (based on D׳Amico criteria) in the National Cancer Database (2010-2012). Primary outcome was NDM (i.e., delayed/no treatment with prostatectomy/radiation therapy or androgen-deprivation monotherapy). Treating facilities were classified by quartiles of proportions of patients treated with advanced technology. Multivariable regression estimated odds of primary outcome based on race, insurance status, and facility-level technology use, and evaluated for interactions between these covariates.
resultsAmong 60,300 patients, 9,265 (15.4%) received NDM. This was more common among non-White men (P<0.001), Medicaid/uninsured patients (P<0.001), and those managed at facilities in the lowest quartile of technology use (25.1% vs. 11.0% highest, P<0.001). Though NDM was common among non-White men with Medicaid/no insurance treated at low-technology centers (43% vs. 10% White, private/Medicare, high-tech facility; adjusted odds ratios = 7.18, P<0.001), this was less likely if this group was managed at a high-tech hospital (22% vs. 43% low-tech, P<0.001).
conclusionsTechnology use at a facility correlates with high-quality prostate cancer care and is associated with diminished disparities based on insurance status and patient race. More research is required to characterize other facility-level factors explaining these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.